For the quarter ending 2025-12-31, AEMD had $1,103,165 increase in cash & cash equivalents over the period. -$1,876,010 in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -2,018,245 | -3,248,958 | - |
| Depreciation and amortization | 81,603 | 79,866 | 82,637 |
| Stock based compensation | 72,442 | 72,442 | 72,442 |
| Net loss | - | - | -1,761,858 |
| Amortization of right-of-use operating lease asset | 73,913 | 145,350 | - |
| Prepaid expenses and other current assets | -344,593 | 82,574 | -164,031 |
| Deferred revenue | - | - | 0 |
| Accounts payable and other current liabilities | -418,055 | -190,287 | -137,492 |
| Accretion of right-of-use operating lease asset | - | - | -72,270 |
| Due to related parties | -10,608 | -124,144 | -206,967 |
| Net cash used in operating activities | -1,874,357 | -1,658,717 | -1,714,937 |
| Purchases of property and equipment | 1,653 | - | - |
| Net cash used investing activities | -1,653 | - | - |
| Proceeds from the issuance of common stock, pre-funded warrants and warrant exercises | 4,005,476 | 3,744,466 | 0 |
| Proceeds from the issuance of common stock upon class a and class b warrant exercises | - | 0 | - |
| Payments for deferred offering costs related to equity issuances | 1,021,602 | - | - |
| Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units | 1,239 | 3,344 | 5,357 |
| Proceeds from the issuance of common stock upon class a and class b warrant exercises | - | - | 0 |
| Net cash provided by financing activities | 2,982,635 | 3,741,122 | -5,357 |
| Effect of exchange rate on changes on cash | -3,460 | 6,252 | -15,496 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 1,103,165 | 2,088,657 | -1,735,790 |
| Cash and cash equivalents at beginning of period | 5,951,941 | 5,599,074 | - |
| Cash and cash equivalents at end of period | 7,055,106 | 5,951,941 | - |
AETHLON MEDICAL INC (AEMD)
AETHLON MEDICAL INC (AEMD)